M. Mazzitelli, E. Arrighi, F. Serapide, M. C. Pelle, B. Tassone, R. Lionello, G. Marrazzo, D. Laganà, F. Costanzo, G. Matera, E. Trecarichi, C. Torti
Journal of medical virology, 2020
Abstract Over the last months, pandemic SARS‐CoV‐2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS‐CoV‐2 infection with associated clinical improvements. We report herein a case series of patients with COVID‐19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.
Cited by 12 publications.
Field of study: Medicine